The Journal of Pediatrics
Volume 153, Issue 2 , Pages S4-S14 , August 2008

Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

  • Philip M. Farrell, MD, PhD

      Affiliations

    • From the Department of Pediatrics and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
    • ,
  • Beryl J. Rosenstein, MD

      Affiliations

    • Department of Pediatrics, Johns Hopkins University, Baltimore, MD
    • ,
  • Terry B. White, PhD

      Affiliations

    • Cystic Fibrosis Foundation, Bethesda, MD
    • Corresponding Author InformationCorrespondence: Terry B. White, PhD, Cystic Fibrosis Foundation, 6931 Arlington Rd, Bethesda, MD 20814.
    • ,
  • Frank J. Accurso, MD

      Affiliations

    • Department of Pediatrics, University of Colorado Health Sciences Center, Denver, CO
    • ,
  • Carlo Castellani, MD

      Affiliations

    • Cystic Fibrosis Center, Civile Maggiore Hospital, Verona, Italy
    • ,
  • Garry R. Cutting, MD

      Affiliations

    • Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD
    • ,
  • Peter R. Durie, MD, FRCP

      Affiliations

    • Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada
    • ,
  • Vicky A. LeGrys, DrA, CLS

      Affiliations

    • Department of Allied Health Sciences, University of North Carolina, Chapel Hill, NC
    • ,
  • John Massie, MBBS, FRACP, PhD

      Affiliations

    • Department of Respiratory Medicine, Royal Children's Hospital, Melbourne, Australia
    • ,
  • Richard B. Parad, MD, MPH

      Affiliations

    • Department of Newborn Medicine, Brigham and Women's Hospital, Boston, MA.
    • ,
  • Michael J. Rock, MD

      Affiliations

    • Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI
    • ,
  • Preston W. Campbell III, MD

      Affiliations

    • Cystic Fibrosis Foundation, Bethesda, MD

References 

  1. Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Two-tiered immunoreactive trypsinogen (IRT/IRT)-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr. 2005;147(Suppl):S83–S88
  2. Parad RB, Comeau AM. Newborn screening for cystic fibrosis. Pediatr Ann. 2003;32:528–535
  3. Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004;113:1573–1581
  4. Cystic Fibrosis Foundation Patient Registry, 2005 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation.
  5. Farrell PM, Lai HC, Li Z, Kosorok MR, Laxova A, Green CG, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough!. J Pediatr. 2005;147(Suppl):S30–S36
  6. Dankert-Roelse JE, Mérelle ME. Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr. 2005;147(Suppl):S15–S20
  7. Rosenfeld M. Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr. 2005;147(Suppl):S11–S14
  8. Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr. 2005;147(Suppl):S37–S41
  9. Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC. Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. Genet Med. 2002;4:90–94
  10. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax. 2006;61:627–635
  11. Parad RB, Comeau AM. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. J Pediatr. 2005;147(Suppl):S78–S82
  12. Rosenstein B, Cutting G. The diagnosis of cystic fibrosis: a consensus statement (Cystic Fibrosis Foundation Consensus Panel). J Pediatr. 1998;132:589–595
  13. Alper OM, Wong LJ, Young S, Pearl M, Graham S, Sherwin J, et al. Identification of novel and rare mutations in California Hispanic and African-American cystic fibrosis patients. Hum Mutat. 2004;24:353;corr 2005;25:223
  14. Groman JD, Karczeski B, Sheridan M, Robinson TE, Fallin MD, Cutting GR. Phenotypic and genetic characterization of patients with features of ”nonclassic” forms of cystic fibrosis. J Pediatr. 2005;146:675–680
  15. Mickle JE, Cutting GR. Genotype–phenotype relationships in cystic fibrosis. Med Clin North Am. 2000;84:597–607
  16. Wang X, Moylan B, Leopold DA, Kim J, Rubenstein RC, Togias A, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA. 2000;284:1814–1819
  17. Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep. 2004;6:231–239
  18. Cipolli M, Castellani C, Wilcken B, Massie J, McKay K, Gruca M, et al. Pancreatic phenotype in cystic fibrosis patients identified by mutation screening. Arch Dis Child. 2007;92:842–846
  19. Comeau AM, Accurso FJ, White TB, Campbell PW, Hoffman G, Parad RB, et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics. 2007;119:495–518
  20. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. Morb Mortal Recomm Rep. 2004;53(RR-13):1–36
  21. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr. 1995;127:965–970
  22. Waters DL, Dorney SF, Gaskin KJ, Gruca MA, O'Halloran M, Wilcken B. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N Engl J Med. 1990;322:303–308
  23. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns WT, et al. Nutritional benefits of neonatal screening for cystic fibrosis (Wisconsin Cystic Fibrosis Neonatal Screening Study Group). N Engl J Med. 1997;337:963–969
  24. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23:545–549
  25. Quinton PM. Chloride impermeability in cystic fibrosis. Nature. 1983;301:421–422
  26. Legrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr. 2007;151:85–89
  27. Clinical Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards). Sweat testing: sample collection and quantitative analysis (Approved guideline). Document C34-A2, National Committee for Clinical Laboratory Standards. 2000;
  28. College of American Pathologists. Chemistry checklist, laboratory accreditation program. Accessed November 6, 2007 http://www.cap.org/apps/docs/laboratory_accreditation/checklists/chemistry_and_toxicology_april2006.pdf
  29. Eng W, LeGrys VA, Schechter MS, Laughon MM, Barker PM. Sweat-testing in preterm and full-term infants less than 6 weeks of age. Pediatr Pulmonol. 2005;40:64–67
  30. Parad RB, Comeau AM, Dorkin HL, Dovey M, Gerstle R, Martin T, et al. Sweat testing newborn infants detected by cystic fibrosis newborn screening. J Pediatr. 2005;147(Suppl):S69–S72
  31. Funk M, LeGrys VA. Testing diagnostic tests: why size matters. J Pediatr. 2005;146:159–162
  32. Barben J, Ammann RA, Metlagel A, Schoeni MH. Conductivity determined by a new sweat analyzer compared to chloride concentrations for the diagnosis of cystic fibrosis. J Pediatr. 2005;146:183–188
  33. Losty HC, Wheatly H, Doull I. The evaluation of a novel conductometric device for the diagnosis of cystic fibrosis. Ann Clin Biochem. 2006;43:375–381
  34. LeGrys VA. Assessing quality assurance for sweat chloride testing. Clin Lab Sci. 1992;5:354–357
  35. LeGrys VA. Stability of chloride in sweat testing. Clin Lab Sci. 1993;6:156–157
  36. Shwachman H, Mahmoodian A. Pilocarpine iontophoresis sweat testing: results of seven years' experience. In:  Rossi E,  Stoll E editor. Modern Problems in Pediatrics. Basel: Karger; 1967;p. 158–182
  37. Mishra A, Greaves R, Massie J. The limitations of sweat electrolyte reference intervals for the diagnosis of cystic fibrosis: a systematic review. Clin Biochem Rev. 2007;28:60–76
  38. Massie RJ, Olsen M, Glazner J, Robertson CF, Francis I. Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998). Med J Aust. 2000;172:584–587
  39. Massie RJH, Gaskin KJ, Van Asperen PP, Bayliss U, Wilcken B. The reliability of sweat testing at six weeks following newborn screening for cystic fibrosis in NSW, 1995-1996 [abstract]. Am J Resp Crit Care Med. 1998;157:126
  40. Farrell PM, Koscik RE. Sweat chloride concentrations in infants homozygous or heterozygous for ΔF508 cystic fibrosis. Pediatrics. 1996;97:524–528
  41. Massie J, Gaskin K, Van Asperen P, Wilcken B. Sweat testing following newborn screening for cystic fibrosis. Pediatr Pulmonol. 2000;29:452–456
  42. Padoan RAB, Seia M, Corbetta C. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. Eur J Pediatr. 2002;161:212–215
  43. Massie J, Clements B. Diagnosis of cystic fibrosis after newborn screening: the Australasian experience (Twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group). Pediatr Pulmonol. 2005;39:440–446
  44. Taccetti G, Festini F, Braccini G, Campana S, deMartino M. Sweat testing in newborns positive to neonatal screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed. 2004;89:F463–F464
  45. Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM. Newborn screening for cystic fibrosis in Wisconsin: nine years experience with routine trypsinogen/DNA testing. J Pediatr. 2005;147(Suppl):S73–S77
  46. Hall SK, Stableforth DE, Green A. Sweat sodium and chloride concentrations: essential criteria for the diagnosis of cystic fibrosis in adults. Ann Clin Biochem. 1990;27(Pt 4):318–320
  47. Mishra A, Greaves R, Massie J. Sweat electrolytes: Establishing a reference range in adolescents and adults [abstract]. Aust J Med Sci. 2006;27:171
  48. Rock M, Makholm L, Lai H, Cheng Y. Distribution of sweat chloride values in patients with cystic fibrosis [abstract]. Pediatr Pulmonol. 2003;25(Suppl):337
  49. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med. 1994;331:974–980
  50. Stewart B, Zabner J, Shuber A, Welsh MJ, McCray PB. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med. 1995;151:899–903
  51. Lebecque P, Leal T, De Boeck C, Jaspers M, Cuppens H, Cassiman JJ. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am J Respir Crit Care Med. 2002;165:757–761
  52. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med. 2006;174:787–794
  53. Gilljam M, Ellis L, Corey M, Zielenski J, Durie P, Tullis DE. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest. 2004;126:1215–1224
  54. Nick JA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med. 2005;11:513–518
  55. Bishop MD, Freedman SD, Zielenski J, Ahmed N, Dupuis A, Martin S, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet. 2005;118:372–381
  56. Wong LJ, Wang J, Zhang YH, Hsu E, Heim RA, Bowman CM, et al. Improved detection of CFTR mutations in Southern California Hispanic CF patients. Hum Mutat. 2001;18:296–307
  57. Pignatti PF, Bombieri C, Marigo C, Benetazzo M, Luisetti M. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet. 1995;4:635–639
  58. Miller PW, Hamosh A, Macek M, Greenberger PA, MacLean J, Walden SM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet. 1996;59:45–51
  59. Kiesewetter S, Macek M, Davis C, Curristin SM, Chu CS, Graham C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet. 1993;5:274–278
  60. Massie RJ, Poplawski N, Wilcken B, Goldblatt J, Byrnes C, Robertson C. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J. 2001;17:1195–1200
  61. Scotet V, Audrezet M-P, Roussey M, Rault G, Dirou-Prigent , Journel H, et al. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?. Pediatrics. 2006;118:e1523–e1529
  62. Chmiel JF, Drumm ML, Konstan MW, Ferkol TW, Kercsmar CM. Pitfalls in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis. Pediatrics. 1999;103:823–826
  63. O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R. Early pulmonary manifestation of cystic fibrosis in children with the deltaF508/R117H-7T genotype. Pediatrics. 2006;118:1260–1265
  64. Sokol RZ. Infertility in men with cystic fibrosis. Curr Opin Pulm Med. 2001;7:421–426
  65. Dörk T, Dworniczak B, Aulehla-Scholz C, Wieczorek D, Böhm I, Mayerova A, et al. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet. 1997;100:365–377
  66. Durie PR. Pathophysiology of the pancreas in cystic fibrosis. Neth J Med. 1992;41:97–100
  67. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992;326:1187–1191
  68. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353:1443–1453
  69. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hambridge KM, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr. 1992;120:533–540
  70. Daftary A, Acton J, Heubi J, Amin R. Fecal elastase-1: utility in pancreatic function in cystic fibrosis. J Cyst Fibros. 2006;5:71–76
  71. Kori M, Maayan-Metzger A, Shamir R, Sirota L, Dinari G. Faecal elastase 1 levels in premature and full-term infants. Arch Dis Child Fetal Neonatal Ed. 2003;88:F106–F108
  72. Durie PR, Forstner GG, Gaskin KJ, Moore DJ, Cleghorn GJ, Wong SS, et al. Age-related alterations of immunoreactive pancreatic cationic trypsinogen in sera from cystic fibrosis patients with and without pancreatic insufficiency. Pediatr Res. 1986;20:209–213
  73. Sontag MK, Corey M, Hokanson JE, Marshall JA, Sommer SS, Zerbe GO, et al. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. J Pediatr. 2006;149:650–657
  74. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther. 1995;6:445–455
  75. Wilson DC, Ellis L, Zielenski J, Corey M, Ip WF, Tsui LC, et al. Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements. J Pediatr. 1998;132:596–599
  76. Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, Hunter J, et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol. 2004;37:385–392
  77. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, et al. Cystic fibrosis population carrier screening: 2004 revision of the American College of Medical Genetics mutation panel. Genet Med. 2004;6:387–391
  78. Sims EJ, Clark A, McCormick J, Mehta G, Connett G, Mehta A. Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics. 2007;119:19–28
  79. Farrell PM. The meaning of “early” diagnosis in a new era of cystic fibrosis care. Pediatrics. 2007;119:156–157
  80. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (delta F508). N Engl J Med. 1990;323:1517–1522

 Supported by funds from the Cystic Fibrosis Foundation.

 Please see the Author Disclosure section at the end of this article.

 No reprints are available from the authors.

PII: S0022-3476(08)00398-3

doi: 10.1016/j.jpeds.2008.05.005

The Journal of Pediatrics
Volume 153, Issue 2 , Pages S4-S14 , August 2008

Article Tools

* Image Usage & Resolution